# Peter Verhamme

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-verhamme/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,617 |
| Field | Venous Thromboembolism Diagnosis and Management |
| h-index | 77 |
| i10-index | 320 |
| Last Known Institution | Universitair Ziekenhuis Leuven |
| OpenAlex ID | https://openalex.org/A5057802451 |
| ORCID iD | https://orcid.org/0000-0001-8698-2858 |
| Works | 750 |

## Researcher papers

- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non/)
- [Idarucizumab for Dabigatran Reversal](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/)
- [American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism](https://scholariq.org/papers/american-society-of-hematology-2020-guidelines-for-management-of-venous/)
- [Idarucizumab for Dabigatran Reversal — Full Cohort Analysis](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal-full-cohort-analysis/)
- [Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or/)
- [Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-coronary-artery/)
- [Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes](https://scholariq.org/papers/association-of-office-and-ambulatory-blood-pressure-with-mortality-and/)
- [Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin](https://scholariq.org/papers/safety-of-proton-pump-inhibitors-based-on-a-large-multi-year-randomized-trial-of/)
- [Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study](https://scholariq.org/papers/safety-of-the-oral-factor-xia-inhibitor-asundexian-compared-with-apixaban-in/)
- [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary](https://scholariq.org/papers/the-2018-european-heart-rhythm-association-practical-guide-on-the-use-of-non-2/)

## Researcher topics

- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management-2/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Blood Coagulation and Thrombosis Mechanisms](https://scholariq.org/topics/blood-coagulation-and-thrombosis-mechanisms/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)

## Researcher university

- [Universitair Ziekenhuis Leuven](https://scholariq.org/institutions/universitair-ziekenhuis-leuven/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.